{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:41:05Z","timestamp":1791322865380,"version":"4.3.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T00:00:00Z","timestamp":1463961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T00:00:00Z","timestamp":1463961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/ni.3470","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T13:24:28Z","timestamp":1464096268000},"page":"816-824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":382,"title":["CIS is a potent checkpoint in NK cell\u2013mediated tumor immunity"],"prefix":"10.1038","volume":"17","author":[{"given":"Rebecca B","family":"Delconte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana B","family":"Kolesnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura F","family":"Dagley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Rautela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9990-4477","authenticated-orcid":false,"given":"Eva M","family":"Putz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Stannard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Guo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Firth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ushiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E","family":"Andoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariapia A","family":"Degli-Esposti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip P","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E","family":"Sanvitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Infusini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P D","family":"Liau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond M","family":"Linossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Carotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H D","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Seillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana S","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle T","family":"Belz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew I","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren S","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn S","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6757-0436","authenticated-orcid":false,"given":"Alex N","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5408-6239","authenticated-orcid":false,"given":"Jeffery J","family":"Babon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5267-7211","authenticated-orcid":false,"given":"Nicholas D","family":"Huntington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,23]]},"reference":[{"key":"BFni3470_CR1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R.D., Old, L.J. & Smyth, M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).","journal-title":"Science"},{"key":"BFni3470_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.coi.2015.01.006","volume":"33","author":"DS Shin","year":"2015","unstructured":"Shin, D.S. & Ribas, A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr. Opin. Immunol. 33, 23\u201335 (2015).","journal-title":"Curr. Opin. Immunol."},{"key":"BFni3470_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc.2016.2","volume":"16","author":"NP Restifo","year":"2016","unstructured":"Restifo, N.P., Smyth, M.J. & Snyder, A. Acquired resistance to immunotherapy and future challenges. Nat. Rev. Cancer 16, 121\u2013126 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"BFni3470_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nri3174","volume":"12","author":"E Vivier","year":"2012","unstructured":"Vivier, E., Ugolini, S., Blaise, D., Chabannon, C. & Brossay, L. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239\u2013252 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"BFni3470_CR5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri2154","volume":"7","author":"ND Huntington","year":"2007","unstructured":"Huntington, N.D., Vosshenrich, C.A. & Di Santo, J.P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7, 703\u2013714 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"BFni3470_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/icb.2014.1","volume":"92","author":"ND Huntington","year":"2014","unstructured":"Huntington, N.D. The unconventional expression of IL-15 and its role in NK cell homeostasis. Immunol. Cell Biol. 92, 210\u2013213 (2014).","journal-title":"Immunol. Cell Biol."},{"key":"BFni3470_CR7","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.4049\/jimmunol.176.8.4834","volume":"176","author":"G Verdeil","year":"2006","unstructured":"Verdeil, G., Puthier, D., Nguyen, C., Schmitt-Verhulst, A.M. & Auphan-Anezin, N. STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors. J. Immunol. 176, 4834\u20134842 (2006).","journal-title":"J. Immunol."},{"key":"BFni3470_CR8","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ni1487","volume":"8","author":"ND Huntington","year":"2007","unstructured":"Huntington, N.D. et al. Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat. Immunol. 8, 856\u2013863 (2007).","journal-title":"Nat. Immunol."},{"key":"BFni3470_CR9","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1038\/ncomms5539","volume":"5","author":"P Sathe","year":"2014","unstructured":"Sathe, P. et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat. Commun. 5, 4539 (2014).","journal-title":"Nat. Commun."},{"key":"BFni3470_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.seminoncol.2015.05.015","volume":"42","author":"T Floros","year":"2015","unstructured":"Floros, T. & Tarhini, A.A. Anticancer Cytokines: Biology and Clinical Effects of Interferon-\u03b12, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin. Oncol. 42, 539\u2013548 (2015).","journal-title":"Semin. Oncol."},{"key":"BFni3470_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1073\/pnas.95.1.114","volume":"95","author":"DJ Hilton","year":"1998","unstructured":"Hilton, D.J. et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. USA 95, 114\u2013119 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFni3470_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cytogfr.2013.03.005","volume":"24","author":"EM Linossi","year":"2013","unstructured":"Linossi, E.M., Babon, J.J., Hilton, D.J. & Nicholson, S.E. Suppression of cytokine signaling: the SOCS perspective. Cytokine Growth Factor Rev. 24, 241\u2013248 (2013).","journal-title":"Cytokine Growth Factor Rev."},{"key":"BFni3470_CR13","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1073\/pnas.96.5.2071","volume":"96","author":"JG Zhang","year":"1999","unstructured":"Zhang, J.G. et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA 96, 2071\u20132076 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFni3470_CR14","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/emboj\/18.5.1309","volume":"18","author":"H Yasukawa","year":"1999","unstructured":"Yasukawa, H. et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18, 1309\u20131320 (1999).","journal-title":"EMBO J."},{"key":"BFni3470_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nsmb.2519","volume":"20","author":"NJ Kershaw","year":"2013","unstructured":"Kershaw, N.J. et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat. Struct. Mol. Biol. 20, 469\u2013476 (2013).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFni3470_CR16","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1002\/j.1460-2075.1995.tb07281.x","volume":"14","author":"A Yoshimura","year":"1995","unstructured":"Yoshimura, A. et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14, 2816\u20132826 (1995).","journal-title":"EMBO J."},{"key":"BFni3470_CR17","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.V89.9.3148","volume":"89","author":"A Matsumoto","year":"1997","unstructured":"Matsumoto, A. et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89, 3148\u20133154 (1997).","journal-title":"Blood"},{"key":"BFni3470_CR18","doi-asserted-by":"publisher","first-page":"30266","DOI":"10.1074\/jbc.274.42.30266","volume":"274","author":"MJ Aman","year":"1999","unstructured":"Aman, M.J. et al. CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling. J. Biol. Chem. 274, 30266\u201330272 (1999).","journal-title":"J. Biol. Chem."},{"key":"BFni3470_CR19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/ni.2633","volume":"14","author":"XO Yang","year":"2013","unstructured":"Yang, X.O. et al. The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation. Nat. Immunol. 14, 732\u2013740 (2013).","journal-title":"Nat. Immunol."},{"key":"BFni3470_CR20","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1084\/jem.20150304","volume":"212","author":"DC Palmer","year":"2015","unstructured":"Palmer, D.C. et al. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J. Exp. Med. 212, 2095\u20132113 (2015).","journal-title":"J. Exp. Med."},{"key":"BFni3470_CR21","doi-asserted-by":"crossref","unstructured":"Burns, C.J., Segal, D. & Wilks, A.F. in JAK-STAT Signalling Methods and Protocols (eds S.E. Nicholson & N. A. Nicola) Chapter 7, 99\u2013112 (Human Press, USA, 2013).","DOI":"10.1007\/978-1-62703-242-1_7"},{"key":"BFni3470_CR22","doi-asserted-by":"publisher","first-page":"228ra37","DOI":"10.1126\/scitranslmed.3007240","volume":"6","author":"B Mlecnik","year":"2014","unstructured":"Mlecnik, B. et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl. Med. 6, 228ra37 (2014).","journal-title":"Sci. Transl. Med."},{"key":"BFni3470_CR23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949\u2013954 (2002).","journal-title":"Nature"},{"key":"BFni3470_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFni3470_CR25","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow, M.A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006\u20132017 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFni3470_CR26","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/bjc.2015.124","volume":"112","author":"B Homet Moreno","year":"2015","unstructured":"Homet Moreno, B. & Ribas, A. Anti-programmed cell death protein-1\/ligand-1 therapy in different cancers. Br. J. Cancer 112, 1421\u20131427 (2015).","journal-title":"Br. J. Cancer"},{"key":"BFni3470_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFni3470_CR28","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517\u20132526 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFni3470_CR29","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J.R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFni3470_CR30","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S.L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFni3470_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R.S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"BFni3470_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.smim.2014.02.002","volume":"26","author":"DA Knorr","year":"2014","unstructured":"Knorr, D.A., Bachanova, V., Verneris, M.R. & Miller, J.S. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin. Immunol. 26, 161\u2013172 (2014).","journal-title":"Semin. Immunol."},{"key":"BFni3470_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/ni.2850","volume":"15","author":"CJ Chan","year":"2014","unstructured":"Chan, C.J. et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 15, 431\u2013438 (2014).","journal-title":"Nat. Immunol."},{"key":"BFni3470_CR34","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-15-0944","volume":"6","author":"SJ Blake","year":"2016","unstructured":"Blake, S.J. et al. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 6, 446\u2013459 (2016).","journal-title":"Cancer Discov."},{"key":"BFni3470_CR35","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/ni931","volume":"4","author":"BA Croker","year":"2003","unstructured":"Croker, B.A. et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4, 540\u2013545 (2003).","journal-title":"Nat. Immunol."},{"key":"BFni3470_CR36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0092-8674(00)80047-1","volume":"98","author":"WS Alexander","year":"1999","unstructured":"Alexander, W.S. et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98, 597\u2013608 (1999).","journal-title":"Cell"},{"key":"BFni3470_CR37","doi-asserted-by":"publisher","first-page":"18324","DOI":"10.1073\/pnas.1112064108","volume":"108","author":"E Narni-Mancinelli","year":"2011","unstructured":"Narni-Mancinelli, E. et al. Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc. Natl. Acad. Sci. USA 108, 18324\u201318329 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFni3470_CR38","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.transproceed.2012.01.093","volume":"44","author":"O Boyman","year":"2012","unstructured":"Boyman, O. et al. Selectively expanding subsets of T cells in mice by injection of interleukin-2\/antibody complexes: implications for transplantation tolerance. Transplant. Proc. 44, 1032\u20131034 (2012).","journal-title":"Transplant. Proc."},{"key":"BFni3470_CR39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-1-62703-242-1_17","volume":"967","author":"TB Kolesnik","year":"2013","unstructured":"Kolesnik, T.B. & Nicholson, S.E. Analysis of Suppressor of Cytokine Signalling (SOCS) gene expression by real-time quantitative PCR. Methods Mol. Biol. 967, 235\u2013248 (2013).","journal-title":"Methods Mol. Biol."},{"key":"BFni3470_CR40","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1182\/blood.V86.10.3698.bloodjournal86103698","volume":"86","author":"SE Nicholson","year":"1995","unstructured":"Nicholson, S.E., Novak, U., Ziegler, S.F. & Layton, J.E. Distinct regions of the granulocyte colony-stimulating factor receptor are required for tyrosine phosphorylation of the signaling molecules JAK2, Stat3, and p42, p44MAPK. Blood 86, 3698\u20133704 (1995).","journal-title":"Blood"},{"key":"BFni3470_CR41","doi-asserted-by":"publisher","first-page":"e70536","DOI":"10.1371\/journal.pone.0070536","volume":"8","author":"EM Linossi","year":"2013","unstructured":"Linossi, E.M. et al. Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. PLoS One 8, e70536 (2013).","journal-title":"PLoS One"},{"key":"BFni3470_CR42","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1016\/j.bmcl.2009.08.071","volume":"19","author":"CJ Burns","year":"2009","unstructured":"Burns, C.J. et al. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg. Med. Chem. Lett. 19, 5887 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFni3470_CR43","unstructured":"Cytopia Research. Phenyl amino pyrimidine compounds and uses thereof. US Patent WO2008\/109943 A1 (2008)."},{"key":"BFni3470_CR44","unstructured":"Schirle, M. et al. in Kinase Inhibitors Vol. 795 Methods in Molecular Biology (ed Bernhard Kuster) Chapter 11, 161\u2013177 (Humana Press, 2012)."},{"key":"BFni3470_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nmeth.1322","volume":"6","author":"JR Wi\u015bniewski","year":"2009","unstructured":"Wi\u015bniewski, J.R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. Nat. Methods 6, 359\u2013362 (2009).","journal-title":"Nat. Methods"},{"key":"BFni3470_CR46","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1021\/pr101065j","volume":"10","author":"J Cox","year":"2011","unstructured":"Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794\u20131805 (2011).","journal-title":"J. Proteome Res."},{"key":"BFni3470_CR47","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367\u20131372 (2008).","journal-title":"Nat. Biotechnol."},{"key":"BFni3470_CR48","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","volume":"13","author":"J Cox","year":"2014","unstructured":"Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics 13, 2513\u20132526 (2014).","journal-title":"Mol. Cell. Proteomics"},{"key":"BFni3470_CR49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1074\/mcp.M114.041012","volume":"14","author":"EC Keilhauer","year":"2015","unstructured":"Keilhauer, E.C., Hein, M.Y. & Mann, M. Accurate protein complex retrieval by affinity enrichment mass spectrometry (AE-MS) rather than affinity purification mass spectrometry (AP-MS). Mol. Cell. Proteomics 14, 120\u2013135 (2015).","journal-title":"Mol. Cell. Proteomics"},{"key":"BFni3470_CR50","doi-asserted-by":"publisher","first-page":"7637","DOI":"10.1073\/pnas.0601638103","volume":"103","author":"AN Bullock","year":"2006","unstructured":"Bullock, A.N., Debreczeni, J.E., Edwards, A.M., Sundstr\u00f6m, M. & Knapp, S. Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc. Natl. Acad. Sci. USA 103, 7637\u20137642 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFni3470_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-1-60327-394-7_3","volume":"570","author":"SS Li","year":"2009","unstructured":"Li, S.S. & Wu, C. Using peptide array to identify binding motifs and interaction networks for modular domains. Methods Mol. Biol. 570, 67\u201376 (2009).","journal-title":"Methods Mol. Biol."},{"key":"BFni3470_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-1-62703-242-1_3","volume":"967","author":"JJ Babon","year":"2013","unstructured":"Babon, J.J. & Murphy, J.M. In vitro JAK kinase activity and inhibition assays. Methods Mol. Biol. 967, 39\u201355 (2013).","journal-title":"Methods Mol. Biol."},{"key":"BFni3470_CR53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.immuni.2011.12.015","volume":"36","author":"JJ Babon","year":"2012","unstructured":"Babon, J.J. et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36, 239\u2013250 (2012).","journal-title":"Immunity"},{"key":"BFni3470_CR54","doi-asserted-by":"publisher","first-page":"7298","DOI":"10.1158\/0008-5472.CAN-14-1339","volume":"74","author":"L Ferrari de Andrade","year":"2014","unstructured":"Ferrari de Andrade, L. et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res. 74, 7298\u20137308 (2014).","journal-title":"Cancer Res."},{"key":"BFni3470_CR55","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1084\/jem.20081752","volume":"205","author":"S Gilfillan","year":"2008","unstructured":"Gilfillan, S. et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J. Exp. Med. 205, 2965\u20132973 (2008).","journal-title":"J. Exp. Med."},{"key":"BFni3470_CR56","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1158\/0008-5472.CAN-10-4246","volume":"71","author":"J Stagg","year":"2011","unstructured":"Stagg, J. et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 71, 2892\u20132900 (2011).","journal-title":"Cancer Res."},{"key":"BFni3470_CR57","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1073\/pnas.1016569108","volume":"108","author":"J Stagg","year":"2011","unstructured":"Stagg, J. et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. USA 108, 7142\u20137147 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFni3470_CR58","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.4049\/jimmunol.178.12.7540","volume":"178","author":"JB Swann","year":"2007","unstructured":"Swann, J.B. et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178, 7540\u20137549 (2007).","journal-title":"J. Immunol."},{"key":"BFni3470_CR59","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/2326-6066.CIR-15-0065","volume":"3","author":"J Rautela","year":"2015","unstructured":"Rautela, J. et al. Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer. Cancer Immunol. Res. 3, 1207\u20131217 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"BFni3470_CR60","first-page":"237","volume":"8","author":"CN Johnstone","year":"2015","unstructured":"Johnstone, C.N. et al. Functional and molecular characterisation of EO771.LMB tumours, a new C57BL\/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis. Model. Mech. 8, 237\u2013251 (2015).","journal-title":"Dis. Model. Mech."},{"key":"BFni3470_CR61","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","volume":"19","author":"B Allard","year":"2013","unstructured":"Allard, B., Pommey, S., Smyth, M.J. & Stagg, J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res. 19, 5626\u20135635 (2013).","journal-title":"Clin. Cancer Res."}],"updated-by":[{"DOI":"10.1038\/s41590-023-01714-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000}}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ni.3470.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ni.3470","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ni.3470.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T13:12:21Z","timestamp":1702386741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ni.3470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,23]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFni3470"],"URL":"https:\/\/doi.org\/10.1038\/ni.3470","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41590-023-01714-8","asserted-by":"object"}]},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,23]]},"assertion":[{"value":"24 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41590-023-01714-8","URL":"https:\/\/doi.org\/10.1038\/s41590-023-01714-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.S. has been supported by a scientific research agreement with Bristol Myers Squibb and Medimmune and is a consultant for Kymab, F-star and AMGEN.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}